ATM and Familial prostate cancer: TOPARP-A assessed anti-tumour activity of olaparib in a sporadic metastatic castration-resistant prostate cancer population, whilst TOPARP-B was conducted in a subset with known genomic background, specifically BRCA2 or ATM mutations [130,131].